The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the ...

Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well ...

Equities research analysts at William Blair lifted their FY2024 EPS estimates for Larimar Therapeutics in a research note ...

Analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Larimar Therapeutics in a research report ...

Larimar Therapeutics (LRMR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Larimar Therapeutics, Inc. ( (LRMR) ) has realeased its Q3 earnings. Here is a breakdown of the information Larimar Therapeutics, Inc.

Oct. 30, 2024 (GLOBE NEWSWIRE) -- October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

Indeed, Larimar Therapeutics (NASDAQ:LRMR) stock is up 170% in the last year, providing strong gains for shareholders. Nonetheless, only a fool would ignore the risk that a loss making company ...